BioTuesdays

Category - Feature

Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in...

In conversation with Jerry Ropelato

By Len Zehr As CEO and founder of closely-held WhiteClouds, which operates the largest 3D color printing facility in the world, Jerry Ropelato is passionate about using the technology to create stunning models for the...

In conversation with David Luci

By Len Zehr As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex, which could be the...

In conversation with Charles Haff

By Len Zehr As a senior research analyst at Craig-Hallum Capital Group, Charles Haff covers medical devices and ancillary healthcare services. Previously, he covered medical devices at Dougherty & Company and was a...

In conversation with Amir Ronen

By Len Zehr As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior...

In conversation with Dr. Alan Schwebel

By Len Zehr As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel...

EyeGate developing non-invasive ophthalmic treatments

By Len Zehr EyeGate Pharmaceuticals (NASDAQ:EYEG) is developing a non-invasive drug delivery platform that uses an electrical process, known as iontophoresis, to deliver a corticosteroid to the front-and back-of-the-eye...